Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy HTG Molecular Diagnostics stock | $5.66

Learn how to easily invest in HTG Molecular Diagnostics stock.

HTG Molecular Diagnostics Inc is a diagnostics & research business based in the US. HTG Molecular Diagnostics shares (HTGM) are listed on the NASDAQ and all prices are listed in US Dollars. HTG Molecular Diagnostics employs 83 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in HTG Molecular Diagnostics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HTGM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

HTG Molecular Diagnostics stock price (NASDAQ: HTGM)

Use our graph to track the performance of HTGM stocks over time.

HTG Molecular Diagnostics shares at a glance

Information last updated 2021-10-17.
Latest market close$5.66
52-week range$3.50 - $7.95
50-day moving average $5.98
200-day moving average $5.29
Wall St. target price$9.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.04

Buy HTG Molecular Diagnostics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy HTG Molecular Diagnostics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

HTG Molecular Diagnostics price performance over time

Historical closes compared with the close of $5.66 from 2021-10-22

1 week (2021-10-15) -1.05%
1 month (2021-09-24) -5.82%
3 months (2021-07-23) 5.40%
6 months (2021-04-23) 31.32%
1 year (2020-10-23) 1,741.85%
2 years (2019-10-24) 569.51%
3 years (2018-10-24) 58.99%
5 years (2016-10-24) 133.88%

HTG Molecular Diagnostics financials

Revenue TTM $7.9 million
Gross profit TTM $-1,522,575
Return on assets TTM -28.84%
Return on equity TTM -92.47%
Profit margin -218.12%
Book value $1.88
Market capitalisation $42.4 million

TTM: trailing 12 months

Shorting HTG Molecular Diagnostics shares

There are currently 125,947 HTG Molecular Diagnostics shares held short by investors – that's known as HTG Molecular Diagnostics's "short interest". This figure is 27% down from 172,523 last month.

There are a few different ways that this level of interest in shorting HTG Molecular Diagnostics shares can be evaluated.

HTG Molecular Diagnostics's "short interest ratio" (SIR)

HTG Molecular Diagnostics's "short interest ratio" (SIR) is the quantity of HTG Molecular Diagnostics shares currently shorted divided by the average quantity of HTG Molecular Diagnostics shares traded daily (recently around 35180.726256983). HTG Molecular Diagnostics's SIR currently stands at 3.58. In other words for every 100,000 HTG Molecular Diagnostics shares traded daily on the market, roughly 3580 shares are currently held short.

However HTG Molecular Diagnostics's short interest can also be evaluated against the total number of HTG Molecular Diagnostics shares, or, against the total number of tradable HTG Molecular Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case HTG Molecular Diagnostics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 HTG Molecular Diagnostics shares in existence, roughly 20 shares are currently held short) or 0.0236% of the tradable shares (for every 100,000 tradable HTG Molecular Diagnostics shares, roughly 24 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against HTG Molecular Diagnostics.

Find out more about how you can short HTG Molecular Diagnostics stock.

HTG Molecular Diagnostics share dividends

We're not expecting HTG Molecular Diagnostics to pay a dividend over the next 12 months.

Have HTG Molecular Diagnostics's shares ever split?

HTG Molecular Diagnostics's shares were split on a 1:15 basis on 22 November 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your HTG Molecular Diagnostics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for HTG Molecular Diagnostics shares which in turn could have impacted HTG Molecular Diagnostics's share price.

HTG Molecular Diagnostics share price volatility

Over the last 12 months, HTG Molecular Diagnostics's shares have ranged in value from as little as $3.5 up to $7.95. A popular way to gauge a stock's volatility is its "beta".

HTGM.US volatility(beta: 1.48)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while HTG Molecular Diagnostics's is 1.4804. This would suggest that HTG Molecular Diagnostics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

HTG Molecular Diagnostics overview

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc.

Frequently asked questions

What percentage of HTG Molecular Diagnostics is owned by insiders or institutions?
Currently 12.728% of HTG Molecular Diagnostics shares are held by insiders and 37.097% by institutions.
How many people work for HTG Molecular Diagnostics?
Latest data suggests 83 work at HTG Molecular Diagnostics.
When does the fiscal year end for HTG Molecular Diagnostics?
HTG Molecular Diagnostics's fiscal year ends in December.
Where is HTG Molecular Diagnostics based?
HTG Molecular Diagnostics's address is: 3430 East Global Loop, Tucson, AZ, United States, 85706
What is HTG Molecular Diagnostics's ISIN number?
HTG Molecular Diagnostics's international securities identification number is: US40434H2031
What is HTG Molecular Diagnostics's CUSIP number?
HTG Molecular Diagnostics's Committee on Uniform Securities Identification Procedures number is: 40434H104

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site